HER2 overexpression is associated with worse outcomes in patients with upper tract urothelial carcinoma (UTUC)

Francesco Soria, Marco Moschini, Andrea Haitel, Gregory J. Wirth, Jose A. Karam, Christopher G. Wood, Morgan Rouprêt, Vitaly Margulis, Pierre I. Karakiewicz, Alberto Briganti, Jay D. Raman, Solene Florence Kammerer-Jacquet, Romain Mathieu, Karim Bensalah, Yair Lotan, Mehmet Özsoy, Mesut Remzi, Kilian M. Gust, Shahrokh F. Shariat

Research output: Contribution to journalArticle

13 Scopus citations

Abstract

Purpose: The aim of our study was to evaluate the expression pattern of HER2 overexpression in patients with upper tract urothelial carcinoma (UTUC) and to evaluate its association with clinical outcomes. Methods: This multicenter retrospective study included 732 patients treated with radical nephroureterectomy for UTUC. HER2 expression was assessed using immunohistochemistry and scored according to the HercepTest: Scores of 0 or 1 were considered negative and 2 or 3 as positive. To qualify for 2 scoring, complete membrane staining of more than 10 % of tumor cells at a moderate intensity had to be observed. Results: HER2 was overexpressed in 262 (35.8 %) patients. It was associated with pathologic characteristics such as more advanced T stage (p < 0.001), presence of lymph node metastasis (p = 0.006), high-grade tumor (p < 0.001), tumor necrosis (p = 0.01) and lymphovascular invasion (p = 0.02). Patients with HER2 overexpression had a 1.66-fold increased risk of experiencing disease recurrence (95 % CI 1.24–2.24, p = 0.001), 1.55-fold increased risk of death (95 % CI 1.21–1.99, p = 0.001) and 1.81-fold increased risk of cancer-specific death (95 % CI 1.33–2.48, p < 0.001). On multivariable analysis that adjusted for the effects of standard clinicopathologic variables, HER2 overexpression remained associated with disease recurrence (p = 0.04), overall (p = 0.02) and cancer-specific mortality (p = 0.02). Conclusions: Approximately, one-third of UTUC patients overexpressed HER2. HER2 overexpression was associated with features of clinically and biologically aggressive disease as well as prognosis. HER2 may represent a good marker for therapeutic risk stratification and potentially a target for therapy in some UTUC tumors.

Original languageEnglish (US)
Pages (from-to)251-259
Number of pages9
JournalWorld Journal of Urology
Volume35
Issue number2
DOIs
StatePublished - Feb 1 2017

All Science Journal Classification (ASJC) codes

  • Urology

Fingerprint Dive into the research topics of 'HER2 overexpression is associated with worse outcomes in patients with upper tract urothelial carcinoma (UTUC)'. Together they form a unique fingerprint.

  • Cite this

    Soria, F., Moschini, M., Haitel, A., Wirth, G. J., Karam, J. A., Wood, C. G., Rouprêt, M., Margulis, V., Karakiewicz, P. I., Briganti, A., Raman, J. D., Kammerer-Jacquet, S. F., Mathieu, R., Bensalah, K., Lotan, Y., Özsoy, M., Remzi, M., Gust, K. M., & Shariat, S. F. (2017). HER2 overexpression is associated with worse outcomes in patients with upper tract urothelial carcinoma (UTUC). World Journal of Urology, 35(2), 251-259. https://doi.org/10.1007/s00345-016-1871-x